Alizé Pharma 3 raises €67 million ($75 million) in Series A from a strong international syndicate
ORPHELIA Pharma announces today that it has entered into a collaboration agreement with the epilepsy specialist Desitin GmbH to distribute Kigabeq® in Germany.
ORPHELIA Pharma executes a collaboration and license agreement with Gustave Roussy cancer centre for the development of the first pediatric formulation of temozolomide
This sixth newsletter is packed full of information seeing as the semester has been extremely busy for both the Dominique & Tom Alberici Foundation and our Endowment Fund.
The 17th of may 2019, the board of directors of the Foundation Dominique & Tom Alberici decided to support “le Sourire d’Onja”, “Sauvegarde 69”, and “Au-delà de nos Handicaps”,
We organised the Alberici Foundation Meetings on the 17th and 18th April to celebrate the 10th anniversary of the Alberici Foundation and our 100th project. Thank you to those who joined us on Wednesday evening. Some 280 of us attended the philanthropic evening of music and festivities, and it was great fun. Thanks also to those who support us but were unable to attend!
Alizé Pharma 3 to present data from its AZP-3404 program in syndromes of severe insulin resistance at ENDO 2019
Millendo Therapeutics Initiates Pivotal Phase 2b/3 Clinical Study of Livoletide for the Treatment of Prader-Willi Syndrome.
The 3rd phase, JHAM3, launched in 2018 with a collection of items such as adaptive equipment, games, educational toys and books, stationery, school supplies, clothing and household linen.
The 33 m3 container left France on the 28th December en route for Toamasina in Madagascar, and we distributed the equipment to ten Malagasy organisations during our mission between the 3rd and 17th March.
Millendo Therapeutics Announces ENDO 2019 Presentations on Livoletide for Prader-Willi Syndrome and Nevanimibe for Classic Congenital Adrenal Hyperplasia.